Instylla announced today that it received FDA premarket approval (PMA) for its flagship Embrace hydrogel embolic system (HES). The Bedford, Massachusetts-based company received approval for Embrace for the embolization of hypervascular tumors (HVTs) in peripheral arteries ≤ 5mm. HVTs commonly occur in the liver, kidney, bone and other organs, … [Read more...] about Instylla earns FDA premarket nod for hydrogel embolic system
